ArticleInternational journal of clinical oncology2026
Prognostic stratification of recurrent colorectal liver metastasis: impact of recurrence-free interval, tumor numbers, and size on repeat liver resection.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study investigated the prognostic factors of recurrent colorectal liver metastasis (r-CRLM) and the indications for repeat liver resection (RLR).
methodsIn total, 485 patients underwent initial liver resection (ILR) for CRLM. Among them, 98 with resectable r-CRLM were included in this study. Recurrence-free interval (RFI) was defined as the time between ILR and r-CRLM diagnosis. Long-term outcomes were assessed using overall survival (OS) and time to surgical failure (TSF) as endpoints.
resultsEighty-two patients underwent RLR, and 16 received chemotherapy alone. RLR (P = 0.019, hazard ratio [HR] 0.37) was an independent better prognostic factor for OS in 98 patients. In 82 patients who underwent RLR, the presence of ≥ 3 tumors (P = 0.011, HR 2.28), tumor size ≥ 20 mm (P = 0.004, HR 2.41), and RFI < 180 days (P = 0.006, HR 2.28) were independent prognostic factors for TSF. A score of 1 for each factor could stratify the prognosis of patients who underwent RLR (score 0 group: reference, score 1 group: HR-3.20, and score 2-3 group: HR-6.69). Patients who underwent RLR with scores of 2-3 and those who received chemotherapy alone did not significantly differ in prognosis (P = 0.173).
conclusionsRFI < 180 days, presence of ≥ 3 tumors, and tumor size ≥ 20 mm have a prognostic impact on patients with resectable r-CRLM. The RLR indications should be cautiously considered in patients with these risk factors.
Indexed as
Identifiers
41269485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.